Profile data is unavailable for this security.
About the company
Aptamer Group plc is a United Kingdom-based global developer of aptamer-based ligands. The Company develops custom affinity binders through its Optimer platform to enable new approaches in therapeutics, diagnostics and research applications. The Company's Optimer platform delivers aptamer tools that are enabling researchers and developers across the spectrum of the life sciences. Its Optimer binders have been developed for a range of applications, including therapeutic inhibitors and modulators, drug delivery vehicles, protein purification and separation, biomarker screening and validation, in vitro research, quality control analysis, pharmacokinetic and drug assays, and in vitro diagnostic assays. Its Aptamer Diagnostics division uses the Company's technology to support the development of diagnostic platforms, such as proteomics, lateral flow devices, biosensors and immunoassays, such as enzyme-linked immunosorbent assay (ELISA).
- Revenue in GBP (TTM)1.20m
- Net income in GBP-2.42m
- Incorporated2014
- Employees31.00
- LocationAptamer Group PLCWindmill House, Innovation WayYORK YO10 5BRUnited KingdomGBR
- Phone+44 19 0421 7404
- Websitehttps://www.aptamergroup.co.uk/
Peer analysis
| Company | Revenue (TTM) | Net income (TTM) |
|---|---|---|
| Proteome Sciences plc | 4.53m | -3.33m |
| Rua Life Sciences PLC | 5.17m | -850.00k |
| Verici DX PLC | 1.41m | -5.60m |
| Genedrive PLC | 954.00k | -5.23m |
| Cellbxhealth PLC | 2.62m | -15.78m |
| Abingdon Health PLC | 8.43m | -3.42m |
| Inspiration Healthcare Group PLC | 45.20m | -11.44m |
| Aptamer Group PLC | 1.20m | -2.42m |
| Renalytix PLC | 2.20m | -14.99m |
| Aoti Inc | 46.93m | 1.73m |
| Ondine Biomedical Inc | 1.18m | -12.84m |
| Inspecs Group PLC | 192.83m | -3.31m |
| Creo Medical Group PLC | 2.20m | 12.60m |
Institutional shareholders
| Holder | Shares | % Held |
|---|---|---|
| Oberon Investments Ltd. (GB Investment Management)as of 04 Aug 2025 | 172.05m | 6.38% |
| CRUX Asset Management Ltd.as of 03 Oct 2024 | 100.00m | 3.71% |
| Lansdowne Partners (UK) LLPas of 20 Aug 2024 | 24.34m | 0.90% |
